Follow The Filings

IQV IQVIA

Health Care, filed as IQVIA HLDGS INC (COM), Equity As of 2026 Q3 among managers we track Quote on Google Finance, opens in a new tab

Bought by 3 managers in 2026 Q2, sold by 1

  • 2 Owners
  • #181
  • Max 1.8%
  • Master 0.16%
  • $149M
  • 2 reduce

In 2026 Q3 Greenhaven Associates and Murphy Pohlad trimmed IQVIA.

Who owns this now

Largest portfolio weights among holders, up to 1.8% (Greenhaven Associates). Not free-float ownership.

  1. Greenhaven Associates Reduce 1.8%
  2. Murphy Pohlad Reduce 1.0%

Who owns IQV

Sorted by value, long equity only, as of 2026 Q3.

History
Greenhaven Associates 1.8% Reduce −29.1% 544,925 $147M History
Murphy Pohlad, Murphy Pohlad Asset Management 1.0% Reduce −1.3% 10,797 $2.9M History

2 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by IQV's executives, directors and 10% owners in the last 12 months, from their Form 4s

All IQV insider trades
  • None no insider bought on the open market
  • $51.4M sold by 6 insiders outside a trading plan
  • None no planned (10b5-1) sales
  1. James G. Berkshire See Remarks
    Sale
    $697K 2,668 shares at $261.33 20% of stake
    Traded Sep 2 Filed Sep 4
    ↗
  2. W Richard Staub See Remarks
    Sale
    $1.3M 5,500 shares at $232.68 29% of stake
    Traded Aug 3 Filed Aug 4
    ↗
  3. Bhavik Patel See Remarks
    Sale
    $436K 1,855 shares at $235.27 58% of stake
    Traded Jul 31 Filed Aug 4
    ↗
  4. Eric Sherbet See Remarks
    Sale
    $1.2M 5,000 shares at $249.16 19% of stake
    Traded Jul 29 Filed Jul 31
    ↗
  5. Keriann Cherofsky See Remarks
    Sale
    $137K 558 shares at $245.21 16% of stake
    Traded Jul 29 Filed Jul 31
    ↗
  6. Ari Bousbib See Remarks
    Sale
    $26.1M 106,279 shares at $245.51 11% of stake
    Traded Jul 29 Filed Jul 31
    ↗
  7. Ari Bousbib See Remarks
    Sale
    $8.1M 36,564 shares at $222.43 4.3% of stake
    Traded Dec 18, 2025 Filed Dec 19, 2025
    ↗
  8. Eric Sherbet See Remarks
    Sale
    $879K 4,000 shares at $219.70 13% of stake
    Traded Oct 29, 2025 Filed Oct 31, 2025
    ↗
  9. Ari Bousbib See Remarks
    Sale
    $12.5M 56,557 shares at $220.33 6.4% of stake
    Traded Oct 29, 2025 Filed Oct 31, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 14 stock grants, 14 share withholdings for taxes, 6 sales back to the company, and 5 option exercises.

Congress

4 members of Congress traded IQV in the last three years: 4 buys and 7 sales. 3 members listed it in 2025 annual reports.

All Congress trades
  1. Kevin Hern R-OK-1Joint Sell $15K–$50K Sep 14 filed Sep 25
  2. Kevin Hern R-OK-1Child Sell $1K–$15K Sep 8 filed Sep 25
  3. Kevin Hern R-OK-1Child Sell $1K–$15K Sep 3 filed Sep 25
  4. Kevin Hern R-OK-1Joint Sell $50K–$100K Mar 16 filed Apr 3
  5. Markwayne Mullin R-OKJoint Buy $15K–$50K Dec 29, 2025 filed Jan 16
  6. John Boozman R-ARJoint Partial sale $1K–$15K Oct 2, 2025 filed Nov 15, 2025

SEC filings

Recent issuer filings from EDGAR, 17 shown.

Filed Form Detail Links
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 1.01,2.03,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 1.01,2.03,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc

Source: SEC EDGAR submissions, updated about 14 hours ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $14.98B $15.4B $16.31B
Net income $1.36B $1.37B $1.36B
Net margin * 9.1% 8.9% 8.3%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $5.6B $5.83B $6.25B
Total non-current assets * $21.08B $21.07B $23.7B
Total assets $26.68B $26.9B $29.94B
Total current liabilities $6.49B $6.96B $8.34B
Total non-current liabilities * $14.08B $13.88B $14.98B
Total equity — — $6.5B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $2.15B $2.72B $2.65B
Cash from investing -$1.6B -$1.44B -$2.3B
Cash from financing -$382M -$878M -$150M
Net change in cash $160M $326M $278M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.